Metraipolis › archive › dc_4186451ccd9c

Impact of Switching from Oral to Long-Acting Injectable Cabotegravir and Rilpivirine on the Lipid Profile of HIV-Positive Patients — Europe PMC PMID:41597543

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41597543
DOI
10.3390/microorganisms14010022
License (as archived)
solo-consultazione
Archived
2026-11-07T12:03:25.769Z
SHA-256 of the archived text
12be8774d37bee3561e8fc179a05573f03563a8fa2337251611f831c4ce6b34f
Stable URL of this page
https://metraipolis.com/documento/dc_4186451ccd9c

How to cite

Impact of Switching from Oral to Long-Acting Injectable Cabotegravir and Rilpivirine on the Lipid Profile of HIV-Positive Patients — Europe PMC PMID:41597543 — Europe PMC (en), https://europepmc.org/article/MED/41597543 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4186451ccd9c (Metraipolis archive dc_4186451ccd9c, sha256 12be8774d37bee3561e8fc179a05573f03563a8fa2337251611f831c4ce6b34f)
BibTeX
@misc{dc4186451ccd9c,
  title = {Impact of Switching from Oral to Long-Acting Injectable Cabotegravir and Rilpivirine on the Lipid Profile of HIV-Positive Patients — Europe PMC PMID:41597543},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41597543},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4186451ccd9c; sha256 12be8774d37bee3561e8fc179a05573f03563a8fa2337251611f831c4ce6b34f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41597543. Agents can read the archived copy with the MCP tool read_document.